Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMVseropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant. Letermovir was developed by Aicuris Gmbh & Co.
The API has now reached off-patent status, after being launched in 2017.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Letermovir and many others, contact info@pharmacheminvestor.com